

RESEARCH ARTICLE

Open Access

Expression of the *flp* proteins by *Haemophilus ducreyi* is necessary for virulence in human volunteers

Diane M Janowicz^{1*}, Sean A Cooney¹, Jessica Walsh², Beth Baker³, Barry P Katz¹, Kate R Fortney¹, Beth W Zwickl¹, Sheila Ellinger¹ and Robert S Munson Jr^{3,4}

Abstract

Background: *Haemophilus ducreyi*, the causative agent of the sexually transmitted disease chancroid, contains a *flp* (fimbria like protein) operon that encodes proteins predicted to contribute to adherence and pathogenesis. *H. ducreyi* mutants that lack expression of Flp1 and Flp2 or TadA, which has homology to NTPases of type IV secretion systems, have decreased abilities to attach to and form microcolonies on human foreskin fibroblasts (HFF). A *tadA* mutant is attenuated in its ability to cause disease in human volunteers and in the temperature dependent rabbit model, but a *flp1flp2* mutant is virulent in rabbits. Whether a *flp* deletion mutant would cause disease in humans is not clear.

Results: We constructed 35000HPΔ*flp1-3*, a deletion mutant that lacks expression of all three Flp proteins but has an intact *tad* secretion system. 35000HPΔ*flp1-3* was impaired in its ability to form microcolonies and to attach to HFF in vitro when compared to its parent (35000HP). Complementation of the mutant with *flp1-3* in trans restored the parental phenotype. To test whether expression of Flp1-3 was necessary for virulence in humans, ten healthy adult volunteers were experimentally infected with a fixed dose of 35000HP (ranging from 54 to 67 CFU) on one arm and three doses of 35000HPΔ*flp1-3* (ranging from 63 to 961 CFU) on the other arm. The overall papule formation rate for the parent was 80% (95% confidence interval, CI, 55.2%-99.9%) and for the mutant was 70.0% (95% CI, 50.5%-89.5%) ($P = 0.52$). Mutant papules were significantly smaller (mean, 11.2 mm²) than were parent papules (21.8 mm²) 24 h after inoculation ($P = 0.018$). The overall pustule formation rates were 46.7% (95% CI 23.7-69.7%) at 30 parent sites and 6.7% (95% CI, 0.1-19.1%) at 30 mutant sites ($P = 0.001$).

Conclusion: These data suggest that production and secretion of the Flp proteins contributes to microcolony formation and attachment to HFF cells in vitro. Expression of *flp1-3* is also necessary for *H. ducreyi* to initiate disease and progress to pustule formation in humans. Future studies will focus on how Flp proteins contribute to microcolony formation and attachment in vivo.

Background

The *tad* (tight adherence) locus is present in many Gram-positive and Gram-negative bacteria as well as the Archaea and likely represents an ancient subtype of type IV secretion systems that was horizontally transferred to many bacterial species early in the course of evolution. The *tad* genes are located on a mobile genomic island coined "the widespread colonization island" by Figurski

and coworkers [1]. The functions of the *tad* locus gene products have been best described for *Aggregatibacter* (formerly *Actinobacillus*) *actinomycetemcomitans*, where they are essential for adherence, biofilm formation, and pathogenesis. The Tad proteins are predicted to form a macromolecular transport system for the assembly and secretion of fimbria or pili, which mediate adherence of the organism to different surfaces [2].

Haemophilus ducreyi is a gram-negative coccobacillus that causes the sexually transmitted genital ulcer disease chancroid, which is a public health concern because it increases the risk of transmission and acquisition of

* Correspondence: dmjanowicz@iupui.edu

¹Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN 46202, USA

Full list of author information is available at the end of the article

human immunodeficiency virus-1. *H. ducreyi* contains a 12.8 kb *flp* (fimbria like protein) operon with 15 genes (*flp1-flp2-flp3-orfBC-rcpAB-orfD-tadABCDEFG*) that encode products with homology to proteins encoded by the *tad* locus in *A. actinomycetemcomitans* [3,4]. *H. ducreyi* mutants that lack expression of either Flp1 and Flp2, which encode fimbria like proteins, or *tadA*, which has homology to NTPases of type IV secretion systems, have decreased abilities to attach to human foreskin fibroblasts (HFF) and to form microcolonies on HFF [4,5]. A mutant deficient in the expression of *tadA* was significantly but partially attenuated in the temperature dependent rabbit model of experimental chancroid, while a mutant lacking *flp1* and *flp2* expression was fully virulent in this model [4,5]. Thus, whether Flp-Tad-mediated adherence and/or microcolony formation are critical factors in the virulence of *H. ducreyi* is unclear [6].

In experimental and natural infection in humans, *H. ducreyi* forms aggregates, the first step in microcolony formation, and colocalizes with polymorphonuclear leukocytes and macrophages, which fail to ingest the organism. In human inoculation experiments, a *tadA* mutant is highly attenuated for virulence; whether the observed attenuation is due to the lack of secretion of the Flp proteins or other unidentified effectors by the *tad* locus is unclear [5]. Given the discrepancy in virulence between the *tadA* mutant and the *flp1flp2* mutant in the temperature dependent rabbit model [5], here we constructed and characterized a *flp1-3* deletion mutant. We tested the *flp1-3* mutant for its ability to cause disease in human volunteers and its ability to form microcolonies and adhere to human fibroblasts. Our data indicate that expression of Flps is required for virulence and that Flp-Tad mediated adherence correlates with the virulence of *H. ducreyi* in humans. To our knowledge, this study is the first to provide definitive proof that expression of the Flp proteins is required for the virulence of a bacterial pathogen in humans.

Results

Construction and characterization of 35000HPΔ*flp1-3*

An unmarked, in frame deletion mutant of the *flp1*, *flp2*, and *flp3* genes was constructed in 35000HP using recombinering technology and designated 35000HPΔ*flp1-3* [7,8]. Sequence analysis of 35000HPΔ*flp1-3* confirmed that *flp1*, *flp2* and *flp3* had been replaced by a short ORF that consisted of the upstream region of *flp1*, the start codon of *flp1*, 81 bp encoding a scar peptide, and the last 21 bp of *flp3*, including its stop codon. By qRT-PCR, the expression levels of *tadA* and *tadG*, two genes downstream of *flp3*, were similar in 35000HPΔ*flp1-3* compared to 35000HP (data not shown), suggesting that the remainder of the

flp operon was normally transcribed. 35000HP and 35000HPΔ*flp1-3* demonstrated identical growth rates in broth (data not shown). The LOS profiles and OMP patterns as analyzed by SDS-PAGE were similar for the mutant and the parent (data not shown).

Human inoculation experiments

To determine whether the Flp proteins play a role in pathogenesis, 35000HPΔ*flp1-3* was compared with 35000HP for virulence using a mutant parent comparison trial in the human model of infection. Ten healthy adults (six males, four females; 5 Caucasian, 5 black; age range 32 to 59; mean age ± standard deviation, 48 ± 9 years) volunteered for the study. Three subjects (volunteers 333, 334, and 335) were inoculated in the first iteration, three subjects (volunteers 336, 337, and 338) in the second iteration, one subject (volunteer 341) in the third iteration and three subjects (volunteers 342, 343, and 344) in the fourth iteration. In the first iteration, each subject was infected with a fixed EDD (61 CFU) of 35000HP at three sites on one arm and varying EDDs (63, 125, and 249 CFU) of 35000HPΔ*flp1-3* on the other arm (Table 1). Since the ability of the mutant to form pustules seemed impaired (Table 1), we increased the dose of the mutant in subsequent iterations, as per protocol. In the second iteration, volunteers were inoculated with 65 CFU of the parent and 66, 131, and 262 CFU of the mutant (Table 1). In the third iteration, the volunteer was infected with 67 CFU of 35000HP and 240, 480, and 961 CFU of the mutant (Table 1). In the fourth iteration, volunteers were inoculated with 54 CFU of the parent and 104, 208 and 415 CFU of the mutant (Table 1).

The overall papule formation rate for the parent was 80% (95% confidence interval, CI, 55.2%-99.9%) at 30 sites and for the mutant was 70.0% (95% CI, 50.5%-89.5%) at 30 sites ($P = 0.52$). Mutant papules were significantly smaller (mean, 11.2 mm²) than were parent papules (21.8 mm²) 24 h after inoculation ($P = 0.018$). The overall pustule formation rates were 46.7% (95% CI 23.7-69.7%) at 30 parent sites and 6.7% (95% CI, 0.1-19.1%) at 30 mutant sites ($P = 0.001$). Mutant pustules formed at only two sites in one volunteer. These results indicate that expression of one or more of the *flp1*, *flp2*, and *flp3* genes in the context of the intact secretion/assembly complex is necessary for *H. ducreyi* to initiate disease and progress to pustule formation in humans.

H. ducreyi was recovered intermittently from surface cultures. Of the 30 sites that were inoculated with the parent, 11 (36.7%) yielded at least one positive surface culture, while 3 of 30 mutant sites (10.0%) yielded a positive surface culture ($P = 0.019$). All colonies recovered from sites inoculated with the parent (n = 626) or the mutant (n = 39) and colonies from the parent (n =

Table 1 Response to inoculation of live *H. ducreyi* strains

Volunteer	Gender ^a	Days of Observation	Isolate ^b	Dose (cfu)	No. of Initial Papules	No. of Pustules
333	F	14	P	61	3	1
			M	63-249	2	0
334	M	9	P	61	3	0
			M	63-249	2	0
335	M	7	P	61	3	1
			M	63-249	3	0
336	F	6	P	65	0	0
			M	66-261	3	0
337	M	7	P	65	0	0
			M	66-261	1	0
338	F	8	P	65	3	2
			M	66-261	0	0
341	M	8	P	67	3	2
			M	240-961	3	2 ^c
342	F	7	P	54	3	3
			M	104-415	3	0
343	M	6	P	54	3	3
			M	104-415	2	0
344	M	7	P	54	3	2
			M	104-415	2	0

a, F = female, M = male; b, P = parent, M = mutant

142) and mutant (n = 143) inocula were tested for the presence of *flp1-flp2-flp3* and *fgbA* sequences by colony hybridization. The *fgbA* probe hybridized to all the colonies, while the *flp1-2-3* probe hybridized only to the colonies obtained from the parent inoculated sites or the parent inocula. Thus, there was no cross contamination of mutant and parent sites during the course of the trial.

Deletion of *flp1flp2flp3* affects attachment of 35000HP to HFF cells and microcolony formation

To confirm the phenotype of 35000HPΔ*flp1-3*, we complemented 35000HPΔ*flp1-3* in trans by electroporating it with plasmid pJW1, which encodes the Flp1, Flp2 and Flp3. *flp1*, *flp2*, and *flp3* encode proteins with predicted molecular weights of 9.3 kDa, 8.9 kDa, and 9.9 kDa, respectively. Western blot analysis with a polyclonal sera that binds to Flp1 and Flp2 confirmed that 35000HPΔ*flp1-3*(pLSSK) lacked the ability to express the Flp1 and Flp2 proteins (Figure 1, lane 2) compared to 35000HP(pLSSK) (Figure 1, lane 1). Complementation of 35000HPΔ*flp1-3* with plasmid pJW1 resulted in restoration of the expression of the Flp1 and Flp2 proteins as determined by Western blot (Figure 1, lane 3).

35000HP(pLSSK), 35000HPΔ*flp1-3*(pLSSK), and 35000HPΔ*flp1-3*(pJW1) were also tested for their abilities

to bind confluent HFF monolayers. 35000HPΔ*flp1-3* (pLSSK) significantly attached to HFF cells at lower levels (geomean ± standard deviation, 26.0% ± 15.0%) than did 35000HP(pLSSK) (100% ± 29.0%) (*P* = 0.018) (Figure 2). 35000HPΔ*flp1-3*(pJW1) adhered to HFF cells (92.0% ± 18.0%) at significantly higher levels than 35000HPΔ*flp1-3* (pLSSK) (*P* = 0.010) and at similar levels as 35000HP (pLSSK) (*P* = 0.32) (Figure 2).





Figure 1 Western Blot analysis of Flp1 and Flp2 expression by wild type, mutant, and complemented *H. ducreyi* strains.

Whole-cell lysates were probed with polyclonal rabbit Flp1 antiserum as the primary antibody. Lanes: 1, wild-type 35000HP (pLSSK); 2, 35000HPΔ*flp1-3*(pLSSK); 3, 35000HPΔ*flp1-3*(pJW1). Molecular markers are shown on the left.



35000HP(pLSSK), 35000HPΔflp1-3(pLSSK), and 35000HPΔflp1-3(pJW1) were also compared for their abilities to form microcolonies after 24 h incubation with confluent HFF monolayers. 35000HP formed numerous, densely populated microcolonies on the surfaces of HFF cells [4] (Figure 3A). 35000HPΔflp1-3(pLSSK) formed sparse and very small microcolonies (Figure 3B) when compared to 35000HP; the complemented mutant demonstrated a restored phenotype


similar to 35000HP(pLSSK) (Figure 3C). Thus, complementation of the mutant restored the parental phenotypes.

Discussion

For this study, we focused on whether the expression of the Flp proteins was necessary for virulence of *H. ducreyi*. We constructed an unmarked, in frame deletion mutant lacking the *flp1flp2flp3* genes in 35000HP using a recombineering strategy [8,9] and found that 35000HPΔflp1-3 was significantly impaired in its ability to cause disease in the human model of infection. *flp1-3* joins *hgbA*, *dsrA*, *ncaA*, *lspA1-lspA2*, *pal*, *tadA* *sapBC* and *cpxA* as the ninth gene required for full virulence by *H. ducreyi* in the human inoculation experiments [9,10] (unpublished observations).

The *flp-tad* gene cluster is constitutively transcribed as a single polycistronic operon in vitro [4]. Relative to its expression during in vitro growth, *tadA* transcripts are enriched in experimental pustules, suggesting that the *flp-tad* operon is upregulated in vivo [11]. CpxRA is the only obvious intact two-component signal transduction system contained in *H. ducreyi*. Transcription of *flp1-3* and several other major virulence determinants are negatively regulated by conditions that favor phosphorylation of CpxR [9,12,13]. Purified recombinant CpxR interacts with the promoter regions of the *flp* operon in electrophoretic mobility shift assays [13]. Deletion of *cpxA* leads to loss of CpxA phosphatase activity, activates CpxR, and cripples the ability of *H. ducreyi* to infect humans [9]. In contrast, a *cpxR* deletion mutant has no effect on or upregulates the expression of virulence determinants and is fully virulent in human volunteers [13]. Taken together, the data suggest that the *flp-tad* operon may be upregulated in vivo due to downregulation of CpxRA.

The human inoculation experiments are limited in that we are precluded by several regulatory bodies from



testing *trans*-complemented mutants in humans. However, complementation of 35000HP Δ *flp1-3* in trans restored the ability of the mutant to form microcolonies and bind to HFF cells, suggesting that the phenotype of the mutant is due to the deletion of the *flp* genes. In the human inoculation experiments, we use 35000HP to examine the role of virulence factors in *H. ducreyi* pathogenesis. There are two classes of *H. ducreyi* strains, which express different immunotypes and proteomes [14,15]. Although we were able to amplify *flp1-3* alleles from six class I and three class II strains (data not shown), attempts to sequence the amplicons were unsuccessful, so we do not know if there is a difference in the *flp* genes in the class I and class II strains. 35000HP is a class I strain; whether the Flp proteins play a role in the virulence of class II strains is unknown.

We previously reported that a *tadA* mutant is attenuated for pustule formation in the human challenge model [5]. However, the *tadA* mutant, but not a *flp1flp2* double mutant, is attenuated in the rabbit model of chancroid [4,5]. Nika et al previously reported that both the *flp1flp2* mutant and the *tadA* mutant demonstrate decreased abilities to attach to HFF cells and form fewer microcolonies on HFF cells [4]. These data suggested that microcolony formation by itself is not a virulence factor for *H. ducreyi*. Although *H. ducreyi* does not appear to co-localize with fibroblasts in experimental or natural chancroid [16,17], our data indicate that adherence to HFF cells in vitro correlates with the virulence of *H. ducreyi* in humans. Similarly, both *flp1* and *tadA* mutants fail to colonize or cause disease in a rat infection model with *A. actinomycetemcomitans* [1], and both *flp1* mutant and *tadD* mutants of *Pasteurella multocida* are attenuated in the septicemic mouse model [18,19].

In *A. actinomycetemcomitans*, Flp pili are assembled as bundles of long fibers in which Flp1 is the major structural component [3,20]. However, there is no evidence that the Flp proteins are assembled into a pilus-like structure in *H. ducreyi* [4]. Several bacterial species including *A. actinomycetemcomitans* have two *flp* genes [2]. *H. ducreyi* contains three *flp* genes, which have between 50-80% similarity to one another [4]. Deletion of *flp1* and *flp2* results in decreased adherence of *H. ducreyi* to HFF cells and subsequent microcolony formation [4]; the function of Flp3 is unclear.

In vitro, *H. ducreyi* forms microcolonies, a key step in biofilm formation. In vivo, *H. ducreyi* forms aggregates and colocalizes with macrophages, PMNs, collagen and fibrin [16,17]. *H. ducreyi* contains a *luxS* homologue that has autoinducer (AI-2) activity in a *Vibrio harveyi*-based reporter system, and a *luxS* mutant is partially attenuated for virulence in human volunteers [21].

Taken together, these data suggest that the formation of microcolonies, aggregates and quorum sensing mechanisms may be important for *H. ducreyi* pathogenesis. Whether the Flp proteins contribute to this process by mediating attachment to host cells or initiating microcolony formation in the skin remains a subject for future investigation.

Conclusions

We have constructed an unmarked, in frame deletion mutant lacking the *flp1flp2flp3* genes in *H. ducreyi* strain 35000HP. The deletion mutant, 35000HP Δ *flp1-3*, has an intact *tad* secretion system. Our data show that production and secretion of the Flp proteins contributes to microcolony formation and attachment of 35000HP to HFF cells in vitro. Complementation of the mutant with *flp1-3* in trans restored the parental phenotype. Additionally, expression of Flp1-3 is necessary for *H. ducreyi* to initiate disease and progress to pustule formation in humans. Future studies will focus on how Flp proteins contribute to microcolony formation and attachment in vivo.

Methods

Bacteria and culture conditions

35000HP is a human-passaged (HP) variant of strain 35000 and has been reported previously [22]. *H. ducreyi* strains were grown on chocolate agar plates supplemented with 1% IsoVitaleX at 33°C in 5% CO₂. For the human inoculation experiments, *H. ducreyi* was grown in a protease peptone broth-based medium supplemented with 50 µg of hemin per ml, 1% IsoVitaleX and 5% heat-inactivated fetal calf serum (FCS) as described [23] or in a Columbia broth based medium with 2.5% heat-inactivated FCS for other experiments. When appropriate, the media were supplemented with chloramphenicol, spectinomycin, or kanamycin at 0.3 µg/ml, 200 µg/ml, or 20 µg/ml, respectively, to maintain plasmids or select for chromosomal integration of antibiotic resistance cassettes. *E. coli* strains were grown in Luria-Bertani broth or plates at 37°C, except for strain DY380, which was grown or maintained at 32°C and induced to express λ recombinase at 42°C.

Construction and characterization of a *flp1-3* mutant of strain 35000HP

An unmarked, in frame deletion mutant of the *flp1*, *flp2*, and *flp3* genes was made in *H. ducreyi* strain 35000HP using Flippase (FLP) recombinase technology as described previously [8,9]. Briefly, two 70 bp primers, P1 and P2, were designed for construction of a cassette (Table 2). The 3' end of each of these primers contained 20 bp complementary to regions 5' and 3' of a spectinomycin cassette flanked by FLP Recognition Target (FRT) sites in

Table 2 Primers used in this study

Primer	Sequence
P1	TAACCTAAAAACAACATAATTTATTTATATTTGGAGAAAAAGATATGATTCCGGGGATCCGTCGACC
P2	GTATATATGGCACATATAAATTATGTGTTTTATAATCTACCTTTATTGAATGTAGGCTGGAGCTGCTTCG
P3	CGGTCACGATGGTTCAATGTCT
P4	AGCGTTTGACATCATACCATACT
P5	TGCCTACAGCTCAAGTCACGTAA
P6	CCACTCGAAAGCGAAACTTGT
P7	CATCTCGAGCGCCACTATCCAC
P8	CACTCTAGATTATAATCTACCTTT
P9	GGCTTAATTGCAGTCGCAGTTGCT
P10	GTGCAGCTTACCTACTCCTCCTT
P11	ACTCCGACGCTGATGCAATGAAAG
P12	CAAGCTTATCGATACCGTCGACCT

pRSM2832 [8]. The 5' portion of the P1 and P2 primers were homologous to regions 5' and 3' of *H. ducreyi flp1* and *flp3*, respectively. PCR of pRSM2832 with P1 and P2 yielded a 2 Kb amplicon that contained the spectinomycin cassette flanked by FRT sites and 50 bp of DNA homologous to regions 5' and 3' of *H. ducreyi flp1* and *flp3*, respectively. This amplicon was electroporated into *E. coli* DY380 harboring a cosmid size pBeloBAC clone containing the *flp* operon and flanking DNA. After induction of λ recombinase in this strain, spectinomycin-resistant clones were isolated. One clone was further characterized to demonstrate that the *flp1*, *-2* and *-3* genes were replaced with the spectinomycin cassette, with the exception of the *flp1* start codon and the terminal 21 bp of the *flp3* ORF. The construct was confirmed by sequence analysis.

The pBeloBAC clone containing the insertion/deletion mutation in the *flp* genes was used as a template for PCR. The amplicon containing the insertionally inactivated *flp1flp2flp3* genes and approximately 500 bp of flanking DNA 5' and 3' to the cassette was ligated into the suicide vector, pRSM2072, and then electroporated into 35000HP. Cointegrates were selected by growth on spectinomycin, then resolved by passage on plates containing spectinomycin and 5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside (X-Gal) [24]. Allelic exchange was confirmed by colony PCR.

To make an unmarked mutant, the plasmid, pRSM2975, which contains a temperature sensitive replicon, a kanamycin resistance cassette, and FLP recombinase under the control of the *tet* repressor, was transformed into the mutant [9]. Transformants were selected and maintained at 32°C on chocolate agar containing kanamycin. The FLP recombinase was induced to catalyze excision of the spectinomycin cassette resulting in a short unmarked ORF in place of the *flp1*, *flp2* and *flp3* genes and the plasmid was cured as described previously [9]. Colonies were replica plated on chocolate

agar containing no antibiotics, 200 μ g/ml of spectinomycin, and 20 μ g/ml of kanamycin to identify clones that lost both the temperature sensitive plasmid and the spectinomycin cassette. The plasmid and the spectinomycin cassette were lost in 3/120 (2.5%) of the clones tested. One clone that had a deletion of the expected size by colony PCR was designated 35000HP Δ *flp1-3*.

Lipooligosaccharide (LOS) and outer membrane proteins (OMPs) were prepared from 35000HP and 35000HP Δ *flp1-3* and were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, as described [25]. The growth of parent and mutant in broth cultures were also compared.

RNA isolation and Real Time PCR

Bacterial RNA was prepared from mid-log phase organisms by using TRIzol Reagent (Invitrogen) according to manufacturer's instructions. After isolation, RNA was treated twice with DNaseI (Ambion) for 1 hour at 37°C and then purified by using the RNeasy system (Qiagen). Samples were checked by Agilent analysis. After optimizing primers so that their efficiencies were greater than 95%, we examined the level of transcript expression in RNA isolated from 35000HP and 35000HP Δ *flp1-3*. Using each bacterial RNA, and either the *tadA* primers (P3 and P4) (Table 2) or the *tadG* (P5 and P6) primers (Table 2) and SYBR Green, reactions were performed in triplicate using an ABI PRISM 7000 Sequence Detector (Applied Biosystems). Data were expressed as fold change of *tadA* and *tadG* in the mutant relative to the parent.

Complementation of 35000HP Δ *flp1-3*

To complement 35000HP Δ *flp1-3* in trans, the *flp1*, *flp2* and *flp3* ORFs were amplified using the P7 primer with a *Bam*HI linker and the P8 primer with an *Xho*I linker. The resulting 1.58-kb amplicon was ligated into pCR-

XL-TOPO (Invitrogen, Calsbad, Calif.). Transformants were selected on Luria-Bertani plates supplemented with kanamycin (50 µg/ml). The 1.58 kb insert was released from the vector by digestion with *Bam*HI and *Xho*I, ligated into pLSSK [26], and then transformed into *E. coli* DH5α. The plasmid was confirmed by restriction mapping and designated pJW1. *H. ducreyi* 35000HPΔ*flp1-3* was electroporated with pJW1. As controls, 35000HP and 35000HPΔ*flp1-3* were electroporated with pLSSK. Transformants were selected on chocolate agar plates containing streptomycin (50 µg/ml) and transformants were saved and designated 35000HPΔ*flp1-3* (pJW1), 35000HP(pLSSK) and 35000HPΔ*flp1-3*(pLSSK).

SDS-PAGE and Western Blot Analysis

Whole cell lysates were prepared from 35000HPΔ*flp1-3* (pJW1), 35000HPΔ*flp1-3*(pLSSK), and 35000HP(pLSSK) and subjected to SDS-PAGE as previously described [27]. In Western Blot analysis, whole cell lysates were probed with rabbit polyclonal sera that bind to Flp1 and Flp2 (kindly provided by Eric J. Hansen) as described elsewhere [4].

Human inoculation protocol

Stocks of 35000HP and 35000HPΔ*flp1-3* were prepared according to the US Food and Drug Administration guidelines (BB-IND 13046). For the human inoculation protocol, healthy adult male and female volunteers over 21 years of age were recruited for the study. Subjects gave informed consent for participation and for human immunodeficiency virus (HIV) serology, in accordance with the human experimentation guidelines of the U.S. Department of Health and Human Services and the institutional ethics committee of Indiana University-Purdue University of Indianapolis. The experimental protocol, preparation and inoculation of the bacteria, calculation of the estimated delivered dose (EDD), and clinical observations were all done exactly as described previously [10,28]. Subjects were observed until they reached clinical endpoint, which was defined as resolution of all sites, development of a pustule that was either painful or > 6 mm in diameter, or 14 days after inoculation. Subjects were then treated with one dose of oral ciprofloxacin as described [29]. Comparison of papule and pustule formation rates for the two strains were performed using a logistic regression model with generalized estimating equations (GEE) to account for the correlation among sites within the same individual, as previously described [28]. The GEE sandwich estimate for the standard errors was used to calculate 95% confidence intervals (95% CI) for these rates.

To confirm that the strains contained or lacked the *flp1flp2flp3* genes, colonies from the inocula, surface cultures and biopsy specimens were replica plated and

grown on nitrocellulose filters. Filters were probed with amplicons corresponding to either the *fgbA* (fibrinogen binder A) gene or the deleted portion of the *flp1flp2flp3* genes. The *flp1flp2flp3* and the *fgbA* probes were made using primers P9 and P10 and primers P11 and P12, respectively. Probes were labeled with digoxigenin using the DIG DNA Labeling Kit (Roche Applied Sciences, Penzberg, German) and detected with the DIG Easy Hyb protocol (Roche Applied Sciences) according to the manufacturer's instructions.

Adherence assays

Adherence of bacteria to HFF was measured quantitatively as described previously [4]. Briefly, 24-well tissue culture plates (Costar, Corning, N.Y.) were inoculated with 10⁵ HFF/well and grown to confluence. 35000HPΔ*flp1-3*(pJW1), 35000HPΔ*flp1-3*(pLSSK), and 35000HP(pLSSK) were grown in Columbia broth to an OD₆₆₀ between 0.4 and 0.6 and harvested by centrifugation. Bacterial pellets were suspended using HFF medium and approximately 10⁶ CFU were added to individual wells containing confluent HFF, centrifuged at 500 × *g*, and incubated for 2 h at 33°C. After nonadherent bacteria were removed by washing three times with HFF medium, 1 ml of trypsin-EDTA (Invitrogen) solution was added to each well and the plate was incubated for 5 min to liberate the bound bacteria. Serial dilutions of well contents were plated to quantitate HFF-bound bacteria. Percent adherence was calculated as the ratio of HFF-bound bacteria to initial CFU added per well. A paired Student's *t* test was used for the comparison of strains' abilities to attach to HFF cells.

Microcolony formation assays

Confluent HFF monolayers were prepared and 35000HP (pLSSK), 35000HPΔ*flp1-3*(pLSSK), and 35000HPΔ*flp1-3* (pJW1) were grown as described for the adhesion assays. Bacterial pellets were resuspended in HFF medium to an OD₆₆₀ of 0.1. Approximately 10⁶ CFU for each strain was added to individual wells of confluent HFF cells, centrifuged at 500 × *g* for 4 min, and incubated for 24 h at 33°C. Wells were washed three times with 1 ml HFF medium and then stained with crystal violet [0.25% (wt/vol) crystal violet, 20% (vol/vol) methanol, 0.9% (wt/vol) NaCl, 0.02 M Tris-HCl (pH 7.5)] for 20 min at room temperature.

Potential conflicts of Interest

The authors have no conflicts of interest to report.

Acknowledgements and Funding

We thank Eric Hansen for sharing antibodies used in this work, and S.M. Spinola and M.E. Bauer for their helpful discussions and critical reviews of the manuscript. We thank the volunteers who enrolled in the human

challenge study. This work was supported by National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) grant A1074657 to D.M.J. The human challenge trials were supported by NIH NIAID Public Health Service grant U19 AI31494 and by the Indiana Clinical and Translational Sciences Institute and the Indiana Clinical Research Center (UL RR052761).

Author details

¹Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN 46202, USA. ²Department of Microbiology and Immunology, Indiana University, School of Medicine, Indianapolis, IN 46202, USA. ³The Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio 43205, USA. ⁴Department of Pediatrics, The Ohio State University, Columbus, Ohio 43205, USA.

Authors' contributions

SAC carried out the adherence and microcolony formation assays. JW constructed and characterized the complemented mutant. BB and RSM constructed and characterized the *flp1-3* deletion mutant. KRF prepared the bacterial strains used for the human inoculation experiments and participated in the mutant characterization. BWZ and SE prepared the regulatory documents and performed the clinical observations for the human inoculation experiments. BPK performed the statistical analysis. DMJ and RSM participated in the design of the study and drafted the manuscript. All authors read and approved the final manuscript.

Received: 1 June 2011 Accepted: 22 September 2011

Published: 22 September 2011

References

- Schreiner HC, Sinatra K, Kaplan JB, Furgang D, Kachlany SC, Planet PJ, Perez BA, Figurski DH, Fine DH: **Tight-adherence genes of *Actinobacillus actinomycescomitans* are required for virulence in a rat model.** *Proc Natl Acad Sci USA* 2003, **100**:7295-7300.
- Tomich M, Planet PJ, Figurski DH: **The *tad* locus: postcards from the widespread colonization island.** *Nat Rev Microbiol* 2007, **5**:363-375.
- Kachlany SC, Planet PJ, Bhattacharjee MK, Kollia E, DeSalle R, Fine DH, Figurski DH: **Nonspecific adherence by *Actinobacillus actinomycescomitans* requires genes widespread in *Bacteria* and *Archaea*.** *J Bacteriol* 2000, **182**:6169-6176.
- Nika JR, Latimer JL, Ward CK, Blick RJ, Wagner NJ, Cope LD, Mahairas GG, Munson J, Hansen EJ: ***Haemophilus ducreyi* requires the *flp* gene cluster for microcolony formation in vitro.** *Infect Immun* 2002, **70**(6):2965-2975.
- Spinola SM, Fortney KR, Katz BP, Latimer JL, Mock JR, Vakevainen M, Hansen EJ: ***Haemophilus ducreyi* requires an intact *flp* gene cluster for virulence in humans.** *Infect Immun* 2003, **71**:7178-7182.
- Alfa MJ, Stevens MK, Degagne P, Klesney-Tait J, Radolf JD, Hansen EJ: **Use of tissue culture and animal models to identify virulence-associated traits of *Haemophilus ducreyi*.** *Infect Immun* 1995, **63**:1754-1761.
- Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H: **Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection.** *Mol Syst Biol* 2006, **2**:2006 0008.
- Tracy E, Ye F, Baker BD, Munson RS Jr: **Construction of non-polar mutants in *Haemophilus influenzae* using FLP recombinase technology.** *BMC Molecular Biology* 2008, **9**:101.
- Spinola SM, Fortney KR, Baker B, Janowicz DM, Zwickl B, Katz BP, Blick RJ, Munson RS Jr: **Activation of the CpxRA system by deletion of *cpxA* impairs the ability of *Haemophilus ducreyi* to infect humans.** *Infect Immun* 2010, **78**:3898-3904.
- Janowicz DM, Ofner S, Katz BP, Spinola SM: **Experimental infection of human volunteers with *Haemophilus ducreyi*: 15 years of clinical data and experience.** *J Infect Dis* 2009, **199**:1671-1679.
- Bauer ME, Fortney KR, Harrison A, Janowicz DM, Munson RS Jr, Spinola SM: **Identification of *Haemophilus ducreyi* genes expressed during human infection.** *Microbiology* 2008, **154**:1152-1160.
- Labandeira-Rey M, Brautigam CA, Hansen EJ: **Characterization of the CpxRA Regulon in *Haemophilus ducreyi*.** *Infect Immun* 2010, **78**:4779-4791.
- Labandeira-Rey M, Dodd D, Fortney KR, Zwickl B, Katz BP, Janowicz DM, Spinola SM, Hansen EJ: **A *Haemophilus ducreyi* *cpxR* deletion mutant is virulent in human volunteers.** *J Infect Dis* 2011, **203**:1859-1865.
- White CD, Leduc I, Jeter C, Harris C, Elkins C: ***Haemophilus ducreyi* outer membrane determinants, including DsrA, define two clonal populations.** *Infect Immun* 2005, **73**:2387-2399.
- Post DMB, Munson RS Jr, Baker B, Zhong H, Bozue JA, Gibson BW: **Identification of genes involved in the expression of atypical lipooligosaccharide structures from a second class of *Haemophilus ducreyi*.** *Infect Immun* 2007, **75**:113-121.
- Bauer ME, Goheen MP, Townsend CA, Spinola SM: ***Haemophilus ducreyi* associates with phagocytes, collagen, and fibrin and remains extracellular throughout infection of human volunteers.** *Infect Immun* 2001, **69**:2549-2557.
- Bauer ME, Townsend CA, Ronald AR, Spinola SM: **Localization of *Haemophilus ducreyi* in naturally acquired chancroidal ulcers.** *Microbe Infect* 2006, **8**:2465-2468.
- Fuller TE, Kennedy MJ, Lowery DE: **Identification of *Pasteurella multocida* virulence genes in a septicemic mouse model using signature-tagged mutagenesis.** *Microb Pathog* 2000, **29**:25-38.
- Harper M, Boyce JD, Wilkie IW, Adler B: **Signature-tagged mutagenesis of *Pasteurella multocida* identifies mutants displaying differential virulence characteristics in mice and chickens.** *Infect Immun* 2003, **71**:5440-5446.
- Kachlany SC, Planet PJ, DeSalle R, Fine DH, Figurski DH, Kaplan JB: ***flp-1*, the first representative of a new pilin gene subfamily, is required for non-specific adherence of *Actinobacillus actinomycescomitans*.** *Mol Microbiol* 2001, **40**:542-554.
- Labandeira-Rey M, Janowicz DM, Blick RJ, Fortney KR, Zwickl B, Katz BP, Spinola SM, Hansen EJ: **Inactivation of the *Haemophilus ducreyi* *luxS* gene affects the virulence of this pathogen in human subjects.** *J Infect Dis* 2009, **200**:409-416.
- Al-Tawfiq JA, Thornton AC, Katz BP, Fortney KR, Todd KD, Hood AF, Spinola SM: **Standardization of the experimental model of *Haemophilus ducreyi* infection in human subjects.** *J Infect Dis* 1998, **178**:1684-1687.
- Janowicz DM, Fortney KR, Katz BP, Latimer JL, Deng K, Hansen EJ, Spinola SM: **Expression of the LspA1 and LspA2 proteins by *Haemophilus ducreyi* is required for virulence in human volunteers.** *Infect Immun* 2004, **72**:4528-4533.
- Fulcher RA, Cole LE, Janowicz DM, Toffer KL, Fortney KR, Katz BP, Orndorff PE, Spinola SM, Kawula TH: **Expression of *Haemophilus ducreyi* collagen binding outer membrane protein NcaA is required for virulence in swine and human challenge models of chancroid.** *Infect Immun* 2006, **74**:2651-2658.
- Fortney KR, Young RS, Bauer ME, Katz BP, Hood AF, Munson RS Jr, Spinola SM: **Expression of peptidoglycan-associated lipoprotein is required for virulence in the human model of *Haemophilus ducreyi* infection.** *Infect Immun* 2000, **68**:6441-6448.
- Wood GE, Dutro SM, Totten PA: **Target cell range of *Haemophilus ducreyi* hemolysin and its involvement in invasion of human epithelial cells.** *Infect Immun* 1999, **67**:3740-3749.
- Spinola SM, Griffiths GE, Bogdan JA, Menegus MA: **Characterization of an 18,000 molecular-weight outer membrane protein of *Haemophilus ducreyi* that contains a conserved surface-exposed epitope.** *Infect Immun* 1992, **60**:385-391.
- Spinola SM, Bong CTH, Faber AL, Fortney KR, Bennett SL, Townsend CA, Zwickl BE, Billings SD, Humphreys TL, Bauer ME, et al: **Differences in host susceptibility to disease progression in the human challenge model of *Haemophilus ducreyi* infection.** *Infect Immun* 2003, **71**:6658-6663.
- Banks KE, Fortney KR, Baker B, Billings SD, Katz BP, Munson RS Jr, Spinola SM: **The enterobacterial common antigen-like gene cluster of *Haemophilus ducreyi* contributes to virulence in humans.** *J Infect Dis* 2008, **197**:1531-1536.

doi:10.1186/1471-2180-11-208

Cite this article as: Janowicz et al.: Expression of the *flp* proteins by *Haemophilus ducreyi* is necessary for virulence in human volunteers. *BMC Microbiology* 2011 **11**:208.